More on ALMS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.2 Score)

Upcoming Events

- Earnings (11/12/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Alumis (NQ:ALMS)
Delayed: 6.12 -0.19 (3.01%)
Prev. Close $6.31  
Open$6.31 
52 Wk High$ 
52 Wk Low$ 
Day High$6.31 
Day Low$6.01 
P/E N/A  
EPS$ 
Volume2,496,575 

Friends, Peers and Foes (?): BFRG CYCN (more...)

Oct 9, 2026 04:00 AM Alumis shares Phase 3 data on envudeucitinib for plaque psoriasis
Oct 9, 2026 04:00 AM Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Oct 5, 2026 06:43 AM H.C. Wainwright Reiterates Buy Rating on Alumis Inc (ALMS)
Sep 16, 2026 07:55 AM Alumis (ALMS) Reiterated at Overweight by Cantor Fitzgerald
Sep 2, 2026 04:35 PM Guggenheim Downgrades Alumis Inc (ALMS) to Neutral
Sep 2, 2026 07:55 AM Alumis Inc (ALMS) PT Lowered to $37 at Oppenheimer
Sep 2, 2026 06:26 AM Alumis Inc (ALMS) PT Lowered to $29 at Morgan Stanley
Sep 2, 2026 06:17 AM Alumis Inc (ALMS) PT Lowered to $27 at Baird
Sep 2, 2026 05:13 AM Alumis Inc (ALMS) PT Lowered to $25 at Wells Fargo
Sep 1, 2026 07:32 AM Alumis SLE trial fails primary endpoints; subgroup data guides Phase 3
View All Articles

Entities mentioned with ALMS

View All Entities